{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:50:36Z","timestamp":1790621436087,"version":"4.1.0"},"reference-count":236,"publisher":"IMR Press","issue":"10","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>The presence of protein aggregates is a hallmark of many neurodegenerative diseases, including Parkinson\u2019s disease (PD), Alzheimer\u2019s disease (AD), and frontotemporal lobar degeneration (FTLD). Traditionally, each disease has been associated with the aggregation of specific proteins, which serve as disease-specific biomarkers. For example, aggregates of \u03b1-synuclein (\u03b1-syn) are found in \u03b1-synucleinopathies such as PD, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Similarly, AD is characterized by aggregates of amyloid-beta (A\u03b2) and tau proteins. However, it has been observed that these protein aggregates can also occur in other neurodegenerative diseases, contributing to disease progression. For instance, \u03b1-syn aggregates have been detected in AD, Down syndrome, Huntington\u2019s disease, prion diseases, and various forms of FTLD. Similarly, A\u03b2 aggregates have been found in conditions like DLB and PD. Tau aggregates, in addition to being present in primary tauopathies, have been identified in prion diseases, \u03b1-synucleinopathies, and cognitively healthy aged subjects. Finally, aggregates of TDP-43, typically associated with FTLD and amyotrophic lateral sclerosis (ALS), have been observed in AD, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), MSA, DLB, and other neurodegenerative diseases. These findings highlight the complexity of protein aggregation in neurodegeneration and suggest potential interactions and common mechanisms underlying different diseases. A deeper understating of this complex scenario may eventually lead to the identification of a better elucidation of the pathogenetic mechanisms of these devastating conditions and hopefully new therapeutic stragegies.<\/jats:p>","DOI":"10.31083\/j.fbl2810255","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T08:07:39Z","timestamp":1697789259000},"source":"Crossref","is-referenced-by-count":54,"title":["Secondary Protein Aggregates in Neurodegenerative Diseases: Almost the Rule Rather than the Exception"],"prefix":"10.31083","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2820-9880","authenticated-orcid":true,"given":"Fabio","family":"Moda","sequence":"first","affiliation":[{"name":"Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6013-6093","authenticated-orcid":true,"given":"Arianna","family":"Ciullini","sequence":"first","affiliation":[{"name":"Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8422-4552","authenticated-orcid":true,"given":"Ilaria Linda","family":"Dellarole","sequence":"first","affiliation":[{"name":"Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4187-1114","authenticated-orcid":true,"given":"Annalisa","family":"Lombardo","sequence":"first","affiliation":[{"name":"Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Campanella","sequence":"first","affiliation":[{"name":"Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-4536","authenticated-orcid":true,"given":"Giuseppe","family":"Bufano","sequence":"first","affiliation":[{"name":"Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-7124","authenticated-orcid":true,"given":"Federico Angelo","family":"Cazzaniga","sequence":"first","affiliation":[{"name":"Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-0802","authenticated-orcid":true,"given":"Giorgio","family":"Giaccone","sequence":"first","affiliation":[{"name":"Department of Neurology 5 - Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kovacs GG. Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. International Journal of Molecular Sciences. 2016; 17: 189.","DOI":"10.3390\/ijms17020189"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Forno LS. Neuropathology of Parkinson\u2019s disease. Journal of Neuropathology and Experimental Neurology. 1996; 55: 259\u2013272.","DOI":"10.1097\/00005072-199603000-00001"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Jellinger KA. Neuropathology of sporadic Parkinson\u2019s disease: evaluation and changes of concepts. Movement Disorders: Official Journal of the Movement Disorder Society. 2012; 27: 8\u201330.","DOI":"10.1002\/mds.23795"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Tufi R, Gandhi S, de Castro IP, Lehmann S, Angelova PR, Dinsdale D, et al. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson\u2019s disease. Nature Cell Biology. 2014; 16: 157\u2013166.","DOI":"10.1038\/ncb2901"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89: 88\u2013100.","DOI":"10.1212\/WNL.0000000000004058"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A, Robinson JL, et al. Cellular milieu imparts distinct pathological \u03b1-synuclein strains in \u03b1-synucleinopathies. Nature. 2018; 557: 558\u2013563.","DOI":"10.1038\/s41586-018-0104-4"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Malfertheiner K, Stefanova N, Heras-Garvin A. The Concept of \u03b1-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders. Frontiers in Neurology. 2021; 12: 737195.","DOI":"10.3389\/fneur.2021.737195"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lau A, So RWL, Lau HHC, Sang JC, Ruiz-Riquelme A, Fleck SC, et al. \u03b1-Synuclein strains target distinct brain regions and cell types. Nature Neuroscience. 2020; 23: 21\u201331.","DOI":"10.1038\/s41593-019-0541-x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Hoppe SO, Uzuno\u011flu G, Nussbaum-Krammer C. \u03b1-Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies? Biomolecules. 2021; 11: 931.","DOI":"10.3390\/biom11070931"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, et al. Structural and functional characterization of two alpha-synuclein strains. Nature Communications. 2013; 4: 2575.","DOI":"10.1038\/ncomms3575"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Yang Y, Shi Y, Schweighauser M, Zhang X, Kotecha A, Murzin AG, et al. Structures of \u03b1-synuclein filaments from human brains with Lewy pathology. Nature. 2022; 610: 791\u2013795.","DOI":"10.1038\/s41586-022-05319-3"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Morales R, Abid K, Soto C. The prion strain phenomenon: molecular basis and unprecedented features. Biochimica et Biophysica Acta. 2007; 1772: 681\u2013691.","DOI":"10.1016\/j.bbadis.2006.12.006"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Morales R. Prion strains in mammals: Different conformations leading to disease. PLoS Pathogens. 2017; 13: e1006323.","DOI":"10.1371\/journal.ppat.1006323"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson\u2019s disease. Journal of Neurology. 2002; 249: 138\u2013145.","DOI":"10.1007\/PL00007856"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Angeli A, Mencacci NE, Duran R, Aviles-Olmos I, Kefalopoulou Z, Candelario J, et al. Genotype and phenotype in Parkinson\u2019s disease: lessons in heterogeneity from deep brain stimulation. Movement Disorders: Official Journal of the Movement Disorder Society. 2013; 28: 1370\u20131375.","DOI":"10.1002\/mds.25535"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Jellinger KA. Heterogeneity of Multiple System Atrophy: An Update. Biomedicines. 2022; 10: 599.","DOI":"10.3390\/biomedicines10030599"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71: 670\u2013676.","DOI":"10.1212\/01.wnl.0000324625.00404.15"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Gambetti P, Puoti G, Zou WQ. Variably protease-sensitive prionopathy: a novel disease of the prion protein. Journal of Molecular Neuroscience: MN. 2011; 45: 422\u2013424.","DOI":"10.1007\/s12031-011-9543-1"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nature Medicine. 1998; 4: 1157\u20131165.","DOI":"10.1038\/2654"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer\u2019s disease: findings from neuropathological and neuroimaging studies. Journal of Alzheimer\u2019s Disease: JAD. 2014; 42: S421\u2013S429.","DOI":"10.3233\/JAD-141461"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Twohig D, Nielsen HM. \u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease. Molecular Neurodegeneration. 2019; 14: 23.","DOI":"10.1186\/s13024-019-0320-x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science (New York, N.Y.). 2002; 298: 789\u2013791.","DOI":"10.1126\/science.1074069"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nature Medicine. 2021; 27: 954\u2013963.","DOI":"10.1038\/s41591-021-01382-x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Dor\u00e9 V, Krishnadas N, Bourgeat P, Huang K, Li S, Burnham S, et al. Relationship between amyloid and tau levels and its impact on tau spreading. European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 2225\u20132232.","DOI":"10.1007\/s00259-021-05191-9"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D, et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nature Communications. 2022; 13: 6635.","DOI":"10.1101\/2022.01.07.22268767"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Rasmussen J, Mahler J, Beschorner N, Kaeser SA, H\u00e4sler LM, Baumann F, et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer\u2019s disease. Proceedings of the National Academy of Sciences of the United States of America. 2017; 114: 13018\u201313023.","DOI":"10.1073\/pnas.1713215114"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Condello C, Lemmin T, St\u00f6hr J, Nick M, Wu Y, Maxwell AM, et al. Structural heterogeneity and intersubject variability of A\u03b2 in familial and sporadic Alzheimer\u2019s disease. Proceedings of the National Academy of Sciences of the United States of America. 2018; 115: E782\u2013E791.","DOI":"10.1073\/pnas.1714966115"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Condello C, St\u00f6ehr J. A\u03b2 propagation and strains: Implications for the phenotypic diversity in Alzheimer\u2019s disease. Neurobiology of Disease. 2018; 109: 191\u2013200.","DOI":"10.1016\/j.nbd.2017.03.014"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Di Fede G, Catania M, Maderna E, Ghidoni R, Benussi L, Tonoli E, et al. Molecular subtypes of Alzheimer\u2019s disease. Scientific Reports. 2018; 8: 3269.","DOI":"10.1038\/s41598-018-21641-1"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Cohen M, Appleby B, Safar JG. Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer\u2019s disease. Prion. 2016; 10: 9\u201317.","DOI":"10.1080\/19336896.2015.1123371"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiology of Aging. 1997; 18: 351\u2013357.","DOI":"10.1016\/S0197-4580(97)00056-0"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Price JL, McKeel DW, Jr, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging. 2009; 30: 1026\u20131036.","DOI":"10.1016\/j.neurobiolaging.2009.04.002"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Rodrigue KM, Kennedy KM, Devous MD, Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. \u03b2-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012; 78: 387\u2013395.","DOI":"10.1212\/WNL.0b013e318245d295"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Spillantini MG, Goedert M. Tau pathology and neurodegeneration. The Lancet. Neurology. 2013; 12: 609\u2013622.","DOI":"10.1016\/S1474-4422(13)70090-5"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Mez J, Daneshvar DH, Kiernan PT, Abdolmohammadi B, Alvarez VE, Huber BR, et al. Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football. JAMA. 2017; 318: 360\u2013370.","DOI":"10.1001\/jama.2017.8334"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Silva MC, Haggarty SJ. Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies. International Journal of Molecular Sciences. 2020; 21: 8948.","DOI":"10.3390\/ijms21238948"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annual Review of Neuroscience. 2001; 24: 1121\u20131159.","DOI":"10.1146\/annurev.neuro.24.1.1121"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathologica. 2011; 122: 137\u2013153.","DOI":"10.1007\/s00401-011-0839-6"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica. 2014; 128: 755\u2013766.","DOI":"10.1007\/s00401-014-1349-0"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Irwin DJ, Brettschneider J, McMillan CT, Cooper F, Olm C, Arnold SE, et al. Deep clinical and neuropathological phenotyping of Pick disease. Annals of Neurology. 2016; 79: 272\u2013287.","DOI":"10.1002\/ana.24559"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Rankin KP, Mayo MC, Seeley WW, Lee S, Rabinovici G, Gorno-Tempini ML, et al. Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick\u2019s disease. Journal of Molecular Neuroscience: MN. 2011; 45: 594\u2013608.","DOI":"10.1007\/s12031-011-9615-2"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80: 496\u2013503.","DOI":"10.1212\/WNL.0b013e31827f0fd1"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Yoshida M. Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2006; 26: 457\u2013470.","DOI":"10.1111\/j.1440-1789.2006.00743.x"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Kolarova M, Garc\u00eda-Sierra F, Bartos A, Ricny J, Ripova D. Structure and pathology of tau protein in Alzheimer disease. International Journal of Alzheimer\u2019s Disease. 2012; 2012: 731526.","DOI":"10.1155\/2012\/731526"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Hardy J. Testing times for the \u201camyloid cascade hypothesis\u201d. Neurobiology of Aging. 2002; 23: 1073\u20131074.","DOI":"10.1016\/S0197-4580(02)00042-8"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Vaquer-Alicea J, Diamond MI, Joachimiak LA. Tau strains shape disease. Acta Neuropathologica. 2021; 142: 57\u201371.","DOI":"10.1007\/s00401-021-02301-7"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Dugger BN, Dickson DW. Pathology of Neurodegenerative Diseases. Cold Spring Harbor Perspectives in Biology. 2017; 9: a028035.","DOI":"10.1101\/cshperspect.a028035"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Mackenzie IRA, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of Neurology. 2007; 61: 427\u2013434.","DOI":"10.1002\/ana.21147"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Neumann M, Kwong LK, Truax AC, Vanmassenhove B, Kretzschmar HA, Van Deerlin VM, et al. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Journal of Neuropathology and Experimental Neurology. 2007; 66: 177\u2013183.","DOI":"10.1097\/01.jnen.0000248554.45456.58"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Annals of Neurology. 2008; 64: 60\u201370.","DOI":"10.1002\/ana.21425"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. The American Journal of Pathology. 2008; 173: 182\u2013194.","DOI":"10.2353\/ajpath.2008.080003"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience. 2019; 12: 25.","DOI":"10.3389\/fnmol.2019.00025"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409\/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathologica. 2009; 117: 137\u2013149.","DOI":"10.1007\/s00401-008-0477-9"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. Journal of Neuropathology and Experimental Neurology. 2007; 66: 152\u2013157.","DOI":"10.1097\/nen.0b013e31803020b9"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Beel S, Herdewyn S, Fazal R, De Decker M, Moisse M, Robberecht W, et al. Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice. Molecular Neurodegeneration. 2018; 13: 55.","DOI":"10.1186\/s13024-018-0288-y"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013; 79: 416\u2013438.","DOI":"10.1016\/j.neuron.2013.07.033"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Tan RH, Ke YD, Ittner LM, Halliday GM. ALS\/FTLD: experimental models and reality. Acta Neuropathologica. 2017; 133: 177\u2013196.","DOI":"10.1007\/s00401-016-1666-6"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (New York, N.Y.). 2006; 314: 130\u2013133.","DOI":"10.1126\/science.1134108"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Vanden Broeck L, Kleinberger G, Chapuis J, Gistelinck M, Amouyel P, Van Broeckhoven C, et al. Functional complementation in Drosophila to predict the pathogenicity of TARDBP variants: evidence for a loss-of-function mechanism. Neurobiology of Aging. 2015; 36: 1121\u20131129.","DOI":"10.1016\/j.neurobiolaging.2014.09.001"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Ederle H, Dormann D. TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Letters. 2017; 591: 1489\u20131507.","DOI":"10.1002\/1873-3468.12646"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. Journal of the Neurological Sciences. 2019; 399: 217\u2013226.","DOI":"10.1016\/j.jns.2019.02.030"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Jo M, Lee S, Jeon YM, Kim S, Kwon Y, Kim HJ. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Experimental & Molecular Medicine. 2020; 52: 1652\u20131662.","DOI":"10.1038\/s12276-020-00513-7"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica. 2010; 119: 1\u20134.","DOI":"10.1007\/s00401-009-0612-2"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Mackenzie IRA, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. Journal of Neurochemistry. 2016; 138: 54\u201370.","DOI":"10.1111\/jnc.13588"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Cox PA, Davis DA, Mash DC, Metcalf JS, Banack SA. Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Proceedings. Biological Sciences. 2016; 283: 20152397.","DOI":"10.1098\/rspb.2015.2397"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Davis DA, Cox PA, Banack SA, Lecusay PD, Garamszegi SP, Hagan MJ, et al. l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS\/MND. Journal of Neuropathology and Experimental Neurology. 2020; 79: 393\u2013406.","DOI":"10.1093\/jnen\/nlaa002"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ, et al. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York, N.Y.). 2012; 338: 949\u2013953.","DOI":"10.1126\/science.1227157"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Goedert M. NEURODEGENERATION. Alzheimer\u2019s and Parkinson\u2019s diseases: The prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein. Science (New York, N.Y.). 2015; 349: 1255555.","DOI":"10.1126\/science.1255555"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Goedert M, Jakes R, Spillantini MG. The Synucleinopathies: Twenty Years On. Journal of Parkinson\u2019s Disease. 2017; 7: S51\u2013S69.","DOI":"10.3233\/JPD-179005"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Yamazaki M, Arai Y, Baba M, Iwatsubo T, Mori O, Katayama Y, et al. Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. Journal of Neuropathology and Experimental Neurology. 2000; 59: 585\u2013591.","DOI":"10.1093\/jnen\/59.7.585"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Goedert M. Alpha-synuclein and neurodegenerative diseases. Nature Reviews. Neuroscience. 2001; 2: 492\u2013501.","DOI":"10.1038\/35081564"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Forman MS, Schmidt ML, Kasturi S, Perl DP, Lee VMY, Trojanowski JQ. Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. The American Journal of Pathology. 2002; 160: 1725\u20131731.","DOI":"10.1016\/S0002-9440(10)61119-4"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Neumann M, Adler S, Schl\u00fcter O, Kremmer E, Benecke R, Kretzschmar HA. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathologica. 2000; 100: 568\u2013574.","DOI":"10.1007\/s004010000224"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. The American Journal of Pathology. 2000; 157: 361\u2013368.","DOI":"10.1016\/S0002-9440(10)64548-8"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer\u2019s disease patients with mutations in presenilin and amyloid precursor protein genes. The American Journal of Pathology. 1998; 153: 1365\u20131370.","DOI":"10.1016\/S0002-9440(10)65722-7"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Hamilton RL. Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathology (Zurich, Switzerland). 2000; 10: 378\u2013384.","DOI":"10.1111\/j.1750-3639.2000.tb00269.x"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. Alpha-synuclein-positive structures in cases with sporadic Alzheimer\u2019s disease: morphology and its relationship to tau aggregation. Brain Research. 2001; 888: 287\u2013296.","DOI":"10.1016\/S0006-8993(00)03082-1"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. Journal of Neuropathology and Experimental Neurology. 2003; 62: 363\u2013367.","DOI":"10.1093\/jnen\/62.4.363"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. Journal of Neuropathology and Experimental Neurology. 1993; 52: 648\u2013654.","DOI":"10.1097\/00005072-199311000-00012"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Marui W, Iseki E, U\u00e9da K, Kosaka K. Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer\u2019s disease. Journal of the Neurological Sciences. 2000; 174: 81\u201384.","DOI":"10.1016\/S0022-510X(99)00327-5"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Wirths O, Weickert S, Majtenyi K, Havas L, Kahle PJ, Okochi M, et al. Lewy body variant of Alzheimer\u2019s disease: alpha-synuclein in dystrophic neurites of A beta plaques. Neuroreport. 2000; 11: 3737\u20133741.","DOI":"10.1097\/00001756-200011270-00029"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Iseki E. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson\u2019s disease or Alzheimer\u2019s disease. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2004; 24: 72\u201378.","DOI":"10.1111\/j.1440-1789.2003.00530.x"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Mikolaenko I, Pletnikova O, Kawas CH, O\u2019Brien R, Resnick SM, Crain B, et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). Journal of Neuropathology and Experimental Neurology. 2005; 64: 156\u2013162.","DOI":"10.1093\/jnen\/64.2.156"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Mukaetova-Ladinska EB, Hurt J, Jakes R, Xuereb J, Honer WG, Wischik CM. Alpha-synuclein inclusions in Alzheimer and Lewy body diseases. Journal of Neuropathology and Experimental Neurology. 2000; 59: 408\u2013417.","DOI":"10.1093\/jnen\/59.5.408"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer\u2019s and Parkinson\u2019s diseases. PloS one. 2008; 3: e3135.","DOI":"10.1371\/journal.pone.0003135"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"F\u00f6rstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer\u2019s disease. Clinical and pathological findings. The British Journal of Psychiatry: the Journal of Mental Science. 1993; 162: 385\u2013392.","DOI":"10.1192\/bjp.162.3.385"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer\u2019s disease. Neurology. 1998; 51: 351\u2013357.","DOI":"10.1212\/WNL.51.2.351"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996; 47: 1113\u20131124.","DOI":"10.1212\/WNL.47.5.1113"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Cook C, Petrucelli L. A\u03b2 Puts the Alpha in Synuclein. Neuron. 2020; 105: 205\u2013206.","DOI":"10.1016\/j.neuron.2020.01.001"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer\u2019s disease: a clinical and pathologic entity. Neurology. 1990; 40: 1\u20138.","DOI":"10.1212\/WNL.40.1.1"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha-synuclein detect Lewy bodies in many Down\u2019s syndrome brains with Alzheimer\u2019s disease. Annals of Neurology. 1999; 45: 353\u2013357.","DOI":"10.1002\/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Bodhireddy S, Dickson DW, Mattiace L, Weidenheim KM. A case of Down\u2019s syndrome with diffuse Lewy body disease and Alzheimer\u2019s disease. Neurology. 1994; 44: 159\u2013161.","DOI":"10.1212\/WNL.44.1.159"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Raghavan R, Khin-Nu C, Brown A, Irving D, Ince PG, Day K, et al. Detection of Lewy bodies in Trisomy 21 (Down\u2019s syndrome). The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 1993; 20: 48\u201351.","DOI":"10.1017\/S0317167100047405"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Roos RAC. Huntington\u2019s disease: a clinical review. Orphanet Journal of Rare Diseases. 2010; 5: 40.","DOI":"10.1186\/1750-1172-5-40"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Tom\u00e1s-Zapico C, D\u00edez-Zaera M, Ferrer I, G\u00f3mez-Ramos P, Mor\u00e1n MA, Miras-Portugal MT, et al. \u03b1-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington\u2019s disease. Human Molecular Genetics. 2012; 21: 495\u2013510.","DOI":"10.1093\/hmg\/ddr507"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Ch\u00e1nez-C\u00e1rdenas ME, V\u00e1zquez-Contreras E. The Aggregation of Huntingtin and \u03b1-Synuclein. Journal of Biophysics (Hindawi Publishing Corporation: Online). 2012; 2012: 606172.","DOI":"10.1155\/2012\/606172"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Corrochano S, Renna M, Carter S, Chrobot N, Kent R, Stewart M, et al. \u03b1-Synuclein levels modulate Huntington\u2019s disease in mice. Human Molecular Genetics. 2012; 21: 485\u2013494.","DOI":"10.1093\/hmg\/ddr477"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Po\u00e7as GM, Branco-Santos J, Herrera F, Outeiro TF, Domingos PM. \u03b1-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila. Human Molecular Genetics. 2015; 24: 1898\u20131907.","DOI":"10.1093\/hmg\/ddu606"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Breza M, Emmanouilidou E, Leandrou E, Kartanou C, Bougea A, Panas M, et al. Elevated Serum \u03b1-Synuclein Levels in Huntington\u2019s Disease Patients. Neuroscience. 2020; 431: 34\u201339.","DOI":"10.1016\/j.neuroscience.2020.01.037"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Herrera F, Outeiro TF. \u03b1-Synuclein modifies huntingtin aggregation in living cells. FEBS Letters. 2012; 586: 7\u201312.","DOI":"10.1016\/j.febslet.2011.11.019"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Yu D, Zarate N, White A, Coates D, Tsai W, Nanclares C, et al. CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington\u2019s disease. Acta Neuropathologica Communications. 2022; 10: 83.","DOI":"10.1186\/s40478-022-01397-6"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH, et al. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington\u2019s disease patients and transgenic mouse models. Neuroscience Letters. 2000; 289: 29\u201332.","DOI":"10.1016\/S0304-3940(00)01247-7"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Alves S, R\u00e9gulier E, Nascimento-Ferreira I, Hassig R, Dufour N, Koeppen A, et al. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Human Molecular Genetics. 2008; 17: 2071\u20132083.","DOI":"10.1093\/hmg\/ddn106"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Berciano J, Ferrer I. Glial cell cytoplasmic inclusions in SCA2 do not express alpha-synuclein. Journal of Neurology. 2005; 252: 742\u2013744.","DOI":"10.1007\/s00415-005-0747-6"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Grau-Rivera O, Gelpi E, Nos C, Gaig C, Ferrer I, Saiz A, et al. Clinicopathological Correlations and Concomitant Pathologies in Rapidly Progressive Dementia: A Brain Bank Series. Neuro-degenerative Diseases. 2015; 15: 350\u2013360.","DOI":"10.1159\/000439251"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Vital A, Canron MH, Gil R, Hauw JJ, Vital C. A sporadic case of Creutzfeldt-Jakob disease with beta-amyloid deposits and alpha-synuclein inclusions. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2007; 27: 273\u2013277.","DOI":"10.1111\/j.1440-1789.2007.00755.x"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Vega I, Ruiz-Ojeda J, Juste RA, Geijo M, Zarranz JJ, S\u00e1nchez Menoyo JL, et al. Coexistence of mixed phenotype Creutzfeldt-Jakob disease, Lewy body disease and argyrophilic grain disease plus histological features of possible Alzheimer\u2019s disease: a multi-protein disorder in an autopsy case. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2015; 35: 56\u201363.","DOI":"10.1111\/neup.12150"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Rodriguez-Diehl R, Rey MJ, Gironell A, Martinez-Saez E, Ferrer I, S\u00e1nchez-Valle R, et al. \u201cPreclinical\u201d MSA in definite Creutzfeldt-Jakob disease. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2012; 32: 158\u2013163.","DOI":"10.1111\/j.1440-1789.2011.01232.x"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Vital A, Fernagut PO, Canron MH, Joux J, Bezard E, Martin-Negrier ML, et al. The nigrostriatal pathway in Creutzfeldt-Jakob disease. Journal of Neuropathology and Experimental Neurology. 2009; 68: 809\u2013815.","DOI":"10.1097\/NEN.0b013e3181abdae8"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Kovacs GG, Seguin J, Quadrio I, H\u00f6ftberger R, Kap\u00e1s I, Streichenberger N, et al. Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. Acta Neuropathologica. 2011; 121: 39\u201357.","DOI":"10.1007\/s00401-010-0713-y"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Ha\u00efk S, Brandel JP, Sazdovitch V, Delasnerie-Laupr\u00eatre N, Peoc\u2019h K, Laplanche JL, et al. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology. 2000; 55: 1401\u20131404.","DOI":"10.1212\/WNL.55.9.1401"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Head MW, Lowrie S, Chohan G, Knight R, Scoones DJ, Ironside JW. Variably protease-sensitive prionopathy in a PRNP codon 129 heterozygous UK patient with co-existing tau, \u03b1 synuclein and A\u03b2 pathology. Acta Neuropathologica. 2010; 120: 821\u2013823.","DOI":"10.1007\/s00401-010-0766-y"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Iida T, Doh-ura K, Kawashima T, Abe H, Iwaki T. An atypical case of sporadic Creutzfeldt-Jakob disease with Parkinson\u2019s disease. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2001; 21: 294\u2013297.","DOI":"10.1046\/j.1440-1789.2001.00407.x"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Miguelez-Rodriguez A, Santos-Juanes J, Vicente-Etxenausia I, Perez de Heredia-Go\u00f1i K, Garcia B, Quiros LM, et al. Brains with sporadic Creutzfeldt-Jakob disease and copathology showed a prolonged end-stage of disease. Journal of Clinical Pathology. 2018; 71: 446\u2013450.","DOI":"10.1136\/jclinpath-2017-204794"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Katorcha E, Makarava N, Lee YJ, Lindberg I, Monteiro MJ, Kovacs GG, et al. Cross-seeding of prions by aggregated \u03b1-synuclein leads to transmissible spongiform encephalopathy. PLoS Pathogens. 2017; 13: e1006563.","DOI":"10.1371\/journal.ppat.1006563"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Yamashita S, Sakashita N, Yamashita T, Tawara N, Tasaki M, Kawakami K, et al. Concomitant accumulation of \u03b1-synuclein and TDP-43 in a patient with corticobasal degeneration. Journal of Neurology. 2014; 261: 2209\u20132217.","DOI":"10.1007\/s00415-014-7491-8"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Kasanuki K, Josephs KA, Ferman TJ, Murray ME, Koga S, Konno T, et al. Diffuse Lewy body disease manifesting as corticobasal syndrome: A rare form of Lewy body disease. Neurology. 2018; 91: e268\u2013e279.","DOI":"10.1212\/WNL.0000000000005828"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Ling H, O\u2019Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain: a Journal of Neurology. 2010; 133: 2045\u20132057.","DOI":"10.1093\/brain\/awq123"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Horoupian DS, Wasserstein PH. Alzheimer\u2019s disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration. Acta Neuropathologica. 1999; 98: 317\u2013322.","DOI":"10.1007\/s004010051087"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Tsuboi Y, Ahlskog JE, Apaydin H, Parisi JE, Dickson DW. Lewy bodies are not increased in progressive supranuclear palsy compared with normal controls. Neurology. 2001; 57: 1675\u20131678.","DOI":"10.1212\/WNL.57.9.1675"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Mori H, Oda M, Komori T, Arai N, Takanashi M, Mizutani T, et al. Lewy bodies in progressive supranuclear palsy. Acta Neuropathologica. 2002; 104: 273\u2013278.","DOI":"10.1007\/s00401-002-0555-3"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Gearing M, Olson DA, Watts RL, Mirra SS. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology. 1994; 44: 1015\u20131024.","DOI":"10.1212\/WNL.44.6.1015"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Uchikado H, DelleDonne A, Ahmed Z, Dickson DW. Lewy bodies in progressive supranuclear palsy represent an independent disease process. Journal of Neuropathology and Experimental Neurology. 2006; 65: 387\u2013395.","DOI":"10.1097\/01.jnen.0000218449.17073.43"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Judkins AR, Forman MS, Uryu K, Hinkle DA, Asbury AK, Lee VMY, et al. Co-occurrence of Parkinson\u2019s disease with progressive supranuclear palsy. Acta Neuropathologica. 2002; 103: 526\u2013530.","DOI":"10.1007\/s00401-001-0483-7"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Wilhelmsen KC, Forman MS, Rosen HJ, Alving LI, Goldman J, Feiger J, et al. 17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions. Archives of Neurology. 2004; 61: 398\u2013406.","DOI":"10.1001\/archneur.61.3.398"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Seelaar H, Schelhaas HJ, Azmani A, K\u00fcsters B, Rosso S, Majoor-Krakauer D, et al. TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain: a Journal of Neurology. 2007; 130: 1375\u20131385.","DOI":"10.1093\/brain\/awm024"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Yaguchi M, Okamoto K, Nakazato Y. Frontotemporal dementia with cerebral intraneuronal ubiquitin-positive inclusions but lacking lower motor neuron involvement. Acta Neuropathologica. 2003; 105: 81\u201385.","DOI":"10.1007\/s00401-002-0611-z"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Helferich AM, Ruf WP, Grozdanov V, Freischmidt A, Feiler MS, Zondler L, et al. \u03b1-synuclein interacts with SOD1 and promotes its oligomerization. Molecular Neurodegeneration. 2015; 10: 66.","DOI":"10.1186\/s13024-015-0062-3"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Doherty MJ, Bird TD, Leverenz JB. Alpha-synuclein in motor neuron disease: an immunohistologic study. Acta Neuropathologica. 2004; 107: 169\u2013175.","DOI":"10.1007\/s00401-003-0790-2"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Noda K, Katayama S, Watanabe C, Yamamura Y, Nakamura S, Yonehara S, et al. Pure autonomic failure with motor neuron disease: report of a clinical study and postmortem examination of a patient. Journal of Neurology, Neurosurgery, and Psychiatry. 1996; 60: 351\u2013352.","DOI":"10.1136\/jnnp.60.3.351"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ. Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nature Medicine. 1998; 4: 755\u2013757.","DOI":"10.1038\/nm0798-755"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Chung YH, Joo KM, Kim MJ, Cha CI. Immunohistochemical study on the distribution of alpha-synuclein in the central nervous system of transgenic mice expressing a human Cu\/Zn superoxide dismutase mutation. Neuroscience Letters. 2003; 342: 151\u2013154.","DOI":"10.1016\/S0304-3940(03)00237-4"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Takei YI, Oguchi K, Koshihara H, Hineno A, Nakamura A, Ohara S. \u03b1-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation. Human Pathology. 2013; 44: 1171\u20131176.","DOI":"10.1016\/j.humpath.2012.10.024"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Yang EJ, Choi SM. \u03b1 -Synuclein Modification in an ALS Animal Model. Evidence-based Complementary and Alternative Medicine: ECAM. 2013; 2013: 259381.","DOI":"10.1155\/2013\/259381"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Kim SH, Jung SY, Lee KW, Lee SH, Cai M, Choi SM, et al. Bee venom effects on ubiquitin proteasome system in hSOD1(G85R)-expressing NSC34 motor neuron cells. BMC Complementary and Alternative Medicine. 2013; 13: 179.","DOI":"10.1186\/1472-6882-13-179"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"Koch Y, Helferich AM, Steinacker P, Oeckl P, Walther P, Weishaupt JH, et al. Aggregated \u03b1-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. The American Journal of Pathology. 2016; 186: 2152\u20132161.","DOI":"10.1016\/j.ajpath.2016.04.008"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"Roberts B, Theunissen F, Mastaglia FL, Akkari PA, Flynn LL. Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics? International Journal of Molecular Sciences. 2022; 23: 9364.","DOI":"10.3390\/ijms23169364"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain: a Journal of Neurology. 2018; 141: 2181\u20132193.","DOI":"10.1093\/brain\/awy146"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"Visanji NP, Lang AE, Kovacs GG. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. Translational Neurodegeneration. 2019; 8: 28.","DOI":"10.1186\/s40035-019-0172-x"},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Irwin DJ, Lee VMY, Trojanowski JQ. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nature Reviews. Neuroscience. 2013; 14: 626\u2013636.","DOI":"10.1038\/nrn3549"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"Aoki S, Liu AW, Zucca A, Zucca S, Wickens JR. Role of Striatal Cholinergic Interneurons in Set-Shifting in the Rat. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2015; 35: 9424\u20139431.","DOI":"10.1523\/JNEUROSCI.0490-15.2015"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"Moussaud S, Jones DR, Moussaud-Lamodi\u00e8re EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration? Molecular Neurodegeneration. 2014; 9: 43.","DOI":"10.1186\/1750-1326-9-43"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"Nonaka T, Masuda-Suzukake M, Hasegawa M. Molecular mechanisms of the co-deposition of multiple pathological proteins in neurodegenerative diseases. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2018; 38: 64\u201371.","DOI":"10.1111\/neup.12427"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"Jamerlan AM, An SSA. A Microplate-Based Approach to Map Interactions between TDP-43 and \u03b1-Synuclein. Journal of Clinical Medicine. 2022; 11: 573.","DOI":"10.3390\/jcm11030573"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"Dhakal S, Wyant CE, George HE, Morgan SE, Rangachari V. Prion-like C-Terminal Domain of TDP-43 and \u03b1-Synuclein Interact Synergistically to Generate Neurotoxic Hybrid Fibrils. Journal of Molecular Biology. 2021; 433: 166953.","DOI":"10.1016\/j.jmb.2021.166953"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. Journal of Neuropathology and Experimental Neurology. 2009; 68: 816\u2013822.","DOI":"10.1097\/NEN.0b013e3181ac10a7"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"Zolochevska O, Taglialatela G. Non-Demented Individuals with Alzheimer\u2019s Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies. Current Pharmaceutical Design. 2016; 22: 4063\u20134068.","DOI":"10.2174\/1381612822666160518142110"},{"key":"ref148","doi-asserted-by":"crossref","unstructured":"Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019; 92: 329\u2013337.","DOI":"10.1212\/WNL.0000000000006926"},{"key":"ref149","doi-asserted-by":"crossref","unstructured":"Maderna E, Cattaneo C, Cacciatore F, Catania M, Di Fede G, Tagliavini F, et al. Divergent cognitive status with the same Braak stage of neurofibrillary pathology: does the pattern of amyloid-\u03b2 deposits make the difference? Journal of Alzheimer\u2019s Disease: JAD. 2015; 43: 375\u2013379.","DOI":"10.3233\/JAD-140540"},{"key":"ref150","doi-asserted-by":"crossref","unstructured":"Armstrong RA. beta-Amyloid (A beta) deposition in elderly non-demented patients and patients with Alzheimer\u2019s disease. Neuroscience Letters. 1994; 178: 59\u201362.","DOI":"10.1016\/0304-3940(94)90289-5"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"Beker N, Ganz A, Hulsman M, Klausch T, Schmand BA, Scheltens P, et al. Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline. JAMA Network Open. 2021; 4: e2031654.","DOI":"10.1001\/jamanetworkopen.2020.31654"},{"key":"ref152","doi-asserted-by":"crossref","unstructured":"Ganz AB, Beker N, Hulsman M, Sikkes S, Netherlands Brain Bank, Scheltens P, et al. Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathologica Communications. 2018; 6: 64.","DOI":"10.1186\/s40478-018-0558-5"},{"key":"ref153","doi-asserted-by":"crossref","unstructured":"Mormino EC, Papp KV. Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer\u2019s Disease. Journal of Alzheimer\u2019s Disease: JAD. 2018; 64: S633\u2013S646.","DOI":"10.3233\/JAD-179928"},{"key":"ref154","doi-asserted-by":"crossref","unstructured":"Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, et al. Amyloid A4 protein and its precursor in Down\u2019s syndrome and Alzheimer\u2019s disease. The New England Journal of Medicine. 1989; 320: 1446\u20131452.","DOI":"10.1056\/NEJM198906013202203"},{"key":"ref155","doi-asserted-by":"crossref","unstructured":"Webb RL, Murphy MP. \u03b2-Secretases, Alzheimer\u2019s Disease, and Down Syndrome. Current Gerontology and Geriatrics Research. 2012; 2012: 362839.","DOI":"10.1155\/2012\/362839"},{"key":"ref156","doi-asserted-by":"crossref","unstructured":"Holland AJ, Hon J, Huppert FA, Stevens F. Incidence and course of dementia in people with Down\u2019s syndrome: findings from a population-based study. Journal of Intellectual Disability Research: JIDR. 2000; 44: 138\u2013146.","DOI":"10.1046\/j.1365-2788.2000.00263.x"},{"key":"ref157","doi-asserted-by":"crossref","unstructured":"McCarron M, McCallion P, Reilly E, Dunne P, Carroll R, Mulryan N. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. Journal of Intellectual Disability Research: JIDR. 2017; 61: 843\u2013852.","DOI":"10.1111\/jir.12390"},{"key":"ref158","doi-asserted-by":"crossref","unstructured":"Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nature Reviews. Neurology. 2019; 15: 135\u2013147.","DOI":"10.1038\/s41582-018-0132-6"},{"key":"ref159","doi-asserted-by":"crossref","unstructured":"Grigorova M, Mak E, Brown SSG, Beresford-Webb J, Hong YT, Fryer TD, et al. Amyloid- \u03b2 and tau deposition influences cognitive and functional decline in Down syndrome. Neurobiology of Aging. 2022; 119: 36\u201345.","DOI":"10.1016\/j.neurobiolaging.2022.07.003"},{"key":"ref160","doi-asserted-by":"crossref","unstructured":"Donaghy PC, Firbank MJ, Thomas AJ, Lloyd J, Petrides G, Barnett N, et al. Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies. Movement Disorders: Official Journal of the Movement Disorder Society. 2018; 33: 1130\u20131138.","DOI":"10.1002\/mds.27403"},{"key":"ref161","doi-asserted-by":"crossref","unstructured":"Biundo R, Weis L, Fiorenzato E, Pistonesi F, Cagnin A, Bertoldo A, et al. The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. Brain Communications. 2021; 3: fcab180.","DOI":"10.1093\/braincomms\/fcab180"},{"key":"ref162","doi-asserted-by":"crossref","unstructured":"Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RKB. Striatal beta-amyloid deposition in Parkinson disease with dementia. Journal of Neuropathology and Experimental Neurology. 2008; 67: 155\u2013161.","DOI":"10.1097\/NEN.0b013e31816362aa"},{"key":"ref163","doi-asserted-by":"crossref","unstructured":"Kalaitzakis ME, Pearce RKB, Gentleman SM. Clinical correlates of pathology in the claustrum in Parkinson\u2019s disease and dementia with Lewy bodies. Neuroscience Letters. 2009; 461: 12\u201315.","DOI":"10.1016\/j.neulet.2009.05.083"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"Lim EW, Aarsland D, Ffytche D, Taddei RN, van Wamelen DJ, Wan YM, et al. Amyloid-\u03b2 and Parkinson\u2019s disease. Journal of Neurology. 2019; 266: 2605\u20132619.","DOI":"10.1007\/s00415-018-9100-8"},{"key":"ref165","doi-asserted-by":"crossref","unstructured":"Melzer TR, Stark MR, Keenan RJ, Myall DJ, MacAskill MR, Pitcher TL, et al. Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson\u2019s Disease. Frontiers in Neurology. 2019; 10: 391.","DOI":"10.3389\/fneur.2019.00391"},{"key":"ref166","doi-asserted-by":"crossref","unstructured":"Mihaescu AS, Valli M, Uribe C, Diez-Cirarda M, Masellis M, Graff-Guerrero A, et al. Beta amyloid deposition and cognitive decline in Parkinson\u2019s disease: a study of the PPMI cohort. Molecular Brain. 2022; 15: 79.","DOI":"10.1186\/s13041-022-00964-1"},{"key":"ref167","doi-asserted-by":"crossref","unstructured":"Piras IS, Bleul C, Schrauwen I, Talboom J, Llaci L, De Both MD, et al. Transcriptional profiling of multiple system atrophy cerebellar tissue highlights differences between the parkinsonian and cerebellar sub-types of the disease. Acta Neuropathologica Communications. 2020; 8: 76.","DOI":"10.1186\/s40478-020-00950-5"},{"key":"ref168","unstructured":"Armstrong RA. Density and spatial pattern of \u03b2-amyloid (A\u03b2) deposits in corticobasal degeneration. Folia Neuropathologica. 2011; 49: 14\u201320."},{"key":"ref169","doi-asserted-by":"crossref","unstructured":"Armstrong RA. The interface between Alzheimer\u2019s disease, normal aging, and related disorders. Current Aging Science. 2008; 1: 122\u2013132.","DOI":"10.2174\/1874609810801020122"},{"key":"ref170","doi-asserted-by":"crossref","unstructured":"Armstrong RA, Lantos PL, Cairns NJ. Overlap between neurodegenerative disorders. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2005; 25: 111\u2013124.","DOI":"10.1111\/j.1440-1789.2005.00605.x"},{"key":"ref171","doi-asserted-by":"crossref","unstructured":"Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS. Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology. 1997; 48: 959\u2013969.","DOI":"10.1212\/WNL.48.4.959"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, Glatzel M. Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neuro-degenerative Diseases. 2008; 5: 347\u2013354.","DOI":"10.1159\/000121389"},{"key":"ref173","doi-asserted-by":"crossref","unstructured":"Bujan B, Hofer MJ, Oertel WH, Pagenstecher A, B\u00fcrk K. Multiple system atrophy of the cerebellar type (MSA-C) with concomitant beta-amyloid and tau pathology. Clinical Neuropathology. 2013; 32: 286\u2013290.","DOI":"10.5414\/NP300572"},{"key":"ref174","doi-asserted-by":"crossref","unstructured":"Matrone C. The paradigm of amyloid precursor protein in amyotrophic lateral sclerosis: The potential role of the _\u2062682YENPTY_\u2062687 motif. Computational and Structural Biotechnology Journal. 2023; 21: 923\u2013930.","DOI":"10.1016\/j.csbj.2023.01.008"},{"key":"ref175","doi-asserted-by":"crossref","unstructured":"Yoon EJ, Park HJ, Kim GY, Cho HM, Choi JH, Park HY, et al. Intracellular amyloid beta interacts with SOD1 and impairs the enzymatic activity of SOD1: implications for the pathogenesis of amyotrophic lateral sclerosis. Experimental & Molecular Medicine. 2009; 41: 611\u2013617.","DOI":"10.3858\/emm.2009.41.9.067"},{"key":"ref176","doi-asserted-by":"crossref","unstructured":"Vargas-George S, Dave KR. Models of cerebral amyloid angiopathy-related intracerebral hemorrhage. Brain Hemorrhages. 2022; 3: 189\u2013199.","DOI":"10.1016\/j.hest.2022.05.001"},{"key":"ref177","doi-asserted-by":"crossref","unstructured":"Weber SA, Patel RK, Lutsep HL. Cerebral amyloid angiopathy: diagnosis and potential therapies. Expert Review of Neurotherapeutics. 2018; 18: 503\u2013513.","DOI":"10.1080\/14737175.2018.1480938"},{"key":"ref178","doi-asserted-by":"crossref","unstructured":"Raposo N, Viguier A, Cuvinciuc V, Calviere L, Cognard C, Bonneville F, et al. Cortical subarachnoid haemorrhage in the elderly: a recurrent event probably related to cerebral amyloid angiopathy. European Journal of Neurology. 2011; 18: 597\u2013603.","DOI":"10.1111\/j.1468-1331.2010.03214.x"},{"key":"ref179","doi-asserted-by":"crossref","unstructured":"Charidimou A, Boulouis G, Gurol ME, Ayata C, Bacskai BJ, Frosch MP, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain: a Journal of Neurology. 2017; 140: 1829\u20131850.","DOI":"10.1093\/brain\/awx047"},{"key":"ref180","doi-asserted-by":"crossref","unstructured":"Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer\u2019s disease: innocent observation or key player? Brain: a Journal of Neurology. 2011; 134: 335\u2013344.","DOI":"10.1093\/brain\/awq321"},{"key":"ref181","doi-asserted-by":"crossref","unstructured":"Yates PA, Desmond PM, Phal PM, Steward C, Szoeke C, Salvado O, et al. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology. 2014; 82: 1266\u20131273.","DOI":"10.1212\/WNL.0000000000000285"},{"key":"ref182","doi-asserted-by":"crossref","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nature Reviews. Neurology. 2020; 16: 30\u201342.","DOI":"10.1038\/s41582-019-0281-2"},{"key":"ref183","doi-asserted-by":"crossref","unstructured":"Ghetti B, Piccardo P, Frangione B, Bugiani O, Giaccone G, Young K, et al. Prion protein amyloidosis. Brain Pathology (Zurich, Switzerland). 1996; 6: 127\u2013145.","DOI":"10.1111\/j.1750-3639.1996.tb00796.x"},{"key":"ref184","doi-asserted-by":"crossref","unstructured":"Ghetti B, Dlouhy SR, Giaccone G, Bugiani O, Frangione B, Farlow MR, et al. Gerstmann-Str\u00e4ussler-Scheinker disease and the Indiana kindred. Brain Pathology (Zurich, Switzerland). 1995; 5: 61\u201375.","DOI":"10.1111\/j.1750-3639.1995.tb00578.x"},{"key":"ref185","doi-asserted-by":"crossref","unstructured":"Giaccone G, Mangieri M, Capobianco R, Limido L, Hauw JJ, Ha\u00efk S, et al. Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Neurobiology of Aging. 2008; 29: 1864\u20131873.","DOI":"10.1016\/j.neurobiolaging.2007.04.026"},{"key":"ref186","doi-asserted-by":"crossref","unstructured":"Kovacs GG, Rahimi J, Str\u00f6bel T, Lutz MI, Regelsberger G, Streichenberger N, et al. Tau pathology in Creutzfeldt-Jakob disease revisited. Brain Pathology (Zurich, Switzerland). 2017; 27: 332\u2013344.","DOI":"10.1111\/bpa.12411"},{"key":"ref187","doi-asserted-by":"crossref","unstructured":"Ghetti B, Tagliavini F, Giaccone G, Bugiani O, Frangione B, Farlow MR, et al. Familial Gerstmann-Str\u00e4ussler-Scheinker disease with neurofibrillary tangles. Molecular Neurobiology. 1994; 8: 41\u201348.","DOI":"10.1007\/BF02778006"},{"key":"ref188","doi-asserted-by":"crossref","unstructured":"Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson\u2019s disease brains with and without dementia. Experimental Neurology. 2010; 225: 210\u2013218.","DOI":"10.1016\/j.expneurol.2010.06.017"},{"key":"ref189","doi-asserted-by":"crossref","unstructured":"Montalbano M, Majmundar L, Sengupta U, Fung L, Kayed R. Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer\u2019s disease, progressive supranuclear palsy, and dementia with Lewy bodies. Brain Pathology (Zurich, Switzerland). 2023; 33: e13112.","DOI":"10.1111\/bpa.13112"},{"key":"ref190","doi-asserted-by":"crossref","unstructured":"Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Mart\u00ed MJ, et al. Confluence of \u03b1-synuclein, tau, and \u03b2-amyloid pathologies in dementia with Lewy bodies. Journal of Neuropathology and Experimental Neurology. 2013; 72: 1203\u20131212.","DOI":"10.1097\/NEN.0000000000000018"},{"key":"ref191","doi-asserted-by":"crossref","unstructured":"Piao YS, Hayashi S, Hasegawa M, Wakabayashi K, Yamada M, Yoshimoto M, et al. Co-localization of alpha-synuclein and phosphorylated tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration. Acta Neuropathologica. 2001; 101: 285\u2013293.","DOI":"10.1007\/s004010000292"},{"key":"ref192","doi-asserted-by":"crossref","unstructured":"Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Gon\u00e7alves SA, Pera M, et al. Tau enhances \u03b1-synuclein aggregation and toxicity in cellular models of synucleinopathy. PloS one. 2011; 6: e26609.","DOI":"10.1371\/journal.pone.0026609"},{"key":"ref193","doi-asserted-by":"crossref","unstructured":"Pan L, Li C, Meng L, Tian Y, He M, Yuan X, et al. Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain: a Journal of Neurology. 2022; 145: 3454\u20133471.","DOI":"10.1093\/brain\/awac171"},{"key":"ref194","doi-asserted-by":"crossref","unstructured":"Yang W, Ang LC, Strong MJ. Tau protein aggregation in the frontal and entorhinal cortices as a function of aging. Brain Research. Developmental Brain Research. 2005; 156: 127\u2013138.","DOI":"10.1016\/j.devbrainres.2005.02.004"},{"key":"ref195","unstructured":"Bu\u00e9e-Scherrer V, Bu\u00e9e L, Hof PR, Leveugle B, Gilles C, Loerzel AJ, et al. Neurofibrillary degeneration in amyotrophic lateral sclerosis\/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. The American Journal of Pathology. 1995; 146: 924\u2013932."},{"key":"ref196","doi-asserted-by":"crossref","unstructured":"Vidal R, Calero M, Piccardo P, Farlow MR, Unverzagt FW, M\u00e9ndez E, et al. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele. Acta Neuropathologica. 2000; 100: 1\u201312.","DOI":"10.1007\/s004010051186"},{"key":"ref197","doi-asserted-by":"crossref","unstructured":"You Y, Perkins A, Cisternas P, Mu\u00f1oz B, Taylor X, You Y, et al. Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy. Acta Neuropathologica Communications. 2019; 7: 26.","DOI":"10.1186\/s40478-019-0680-z"},{"key":"ref198","doi-asserted-by":"crossref","unstructured":"St-Amour I, Turgeon A, Goupil C, Planel E, H\u00e9bert SS. Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease. Acta Neuropathologica. 2018; 135: 249\u2013265.","DOI":"10.1007\/s00401-017-1786-7"},{"key":"ref199","doi-asserted-by":"crossref","unstructured":"Liu P, Smith BR, Huang ES, Mahesh A, Vonsattel JPG, Petersen AJ, et al. A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington\u2019s disease patients. Acta Neuropathologica Communications. 2019; 7: 111.","DOI":"10.1186\/s40478-019-0764-9"},{"key":"ref200","doi-asserted-by":"crossref","unstructured":"Petry S, Nateghi B, Keraudren R, Sergeant N, Planel E, H\u00e9bert SS, et al. Differential Regulation of Tau Exon 2 and 10 Isoforms in Huntington\u2019s Disease Brain. Neuroscience. 2023; 518: 54\u201363.","DOI":"10.1016\/j.neuroscience.2022.07.014"},{"key":"ref201","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJM, Ferrer I, Rozemuller AJM, et al. Huntington\u2019s disease is a four-repeat tauopathy with tau nuclear rods. Nature Medicine. 2014; 20: 881\u2013885.","DOI":"10.1038\/nm.3617"},{"key":"ref202","doi-asserted-by":"crossref","unstructured":"Delacourte A, David JP, Sergeant N, Bu\u00e9e L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer\u2019s disease. Neurology. 1999; 52: 1158\u20131165.","DOI":"10.1212\/WNL.52.6.1158"},{"key":"ref203","doi-asserted-by":"crossref","unstructured":"Nonaka T, Hasegawa M. Prion-like properties of assembled TDP-43. Current Opinion in Neurobiology. 2020; 61: 23\u201328.","DOI":"10.1016\/j.conb.2019.11.018"},{"key":"ref204","doi-asserted-by":"crossref","unstructured":"Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease. Human Genetics. 2016; 135: 851\u2013867.","DOI":"10.1007\/s00439-016-1683-5"},{"key":"ref205","doi-asserted-by":"crossref","unstructured":"Kim HJ, Taylor JP. Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases. Neuron. 2017; 96: 285\u2013297.","DOI":"10.1016\/j.neuron.2017.07.029"},{"key":"ref206","doi-asserted-by":"crossref","unstructured":"Tziortzouda P, Van Den Bosch L, Hirth F. Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nature Reviews. Neuroscience. 2021; 22: 197\u2013208.","DOI":"10.1038\/s41583-021-00431-1"},{"key":"ref207","doi-asserted-by":"crossref","unstructured":"Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer\u2019s disease. Annals of Neurology. 2007; 61: 435\u2013445.","DOI":"10.1002\/ana.21154"},{"key":"ref208","doi-asserted-by":"crossref","unstructured":"Meneses A, Koga S, O\u2019Leary J, Dickson DW, Bu G, Zhao N. TDP-43 Pathology in Alzheimer\u2019s Disease. Molecular Neurodegeneration. 2021; 16: 84.","DOI":"10.1186\/s13024-021-00503-x"},{"key":"ref209","doi-asserted-by":"crossref","unstructured":"Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer\u2019s disease. Acta Neuropathologica. 2014; 127: 811\u2013824.","DOI":"10.1007\/s00401-014-1269-z"},{"key":"ref210","doi-asserted-by":"crossref","unstructured":"Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer\u2019s disease impact clinical features. Annals of Neurology. 2015; 78: 697\u2013709.","DOI":"10.1002\/ana.24493"},{"key":"ref211","doi-asserted-by":"crossref","unstructured":"Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP-43 in Alzheimer\u2019s disease staging scheme. Acta Neuropathologica. 2016; 131: 571\u2013585.","DOI":"10.1007\/s00401-016-1537-1"},{"key":"ref212","doi-asserted-by":"crossref","unstructured":"Guerrero-Mu\u00f1oz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen AA, Sengupta U, Lasagna-Reeves CA, et al. Amyloid-\u03b2 oligomers as a template for secondary amyloidosis in Alzheimer\u2019s disease. Neurobiology of Disease. 2014; 71: 14\u201323.","DOI":"10.1016\/j.nbd.2014.08.008"},{"key":"ref213","doi-asserted-by":"crossref","unstructured":"Shih YH, Tu LH, Chang TY, Ganesan K, Chang WW, Chang PS, et al. TDP-43 interacts with amyloid-\u03b2, inhibits fibrillization, and worsens pathology in a model of Alzheimer\u2019s disease. Nature Communications. 2020; 11: 5950.","DOI":"10.1038\/s41467-020-19786-7"},{"key":"ref214","doi-asserted-by":"crossref","unstructured":"Koper MJ, Tom\u00e9 SO, Gawor K, Belet A, Van Schoor E, Schaeverbeke J, et al. LATE-NC aggravates GVD-mediated necroptosis in Alzheimer\u2019s disease. Acta Neuropathologica Communications. 2022; 10: 128.","DOI":"10.1186\/s40478-022-01432-6"},{"key":"ref215","doi-asserted-by":"crossref","unstructured":"Koga S, Sanchez-Contreras M, Josephs KA, Uitti RJ, Graff-Radford N, van Gerpen JA, et al. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Movement Disorders: Official Journal of the Movement Disorder Society. 2017; 32: 246\u2013255.","DOI":"10.1002\/mds.26809"},{"key":"ref216","doi-asserted-by":"crossref","unstructured":"Riku Y, Iwasaki Y, Ishigaki S, Akagi A, Hasegawa M, Nishioka K, et al. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain: a Journal of Neurology. 2022; 145: 2769\u20132784.","DOI":"10.1093\/brain\/awac091"},{"key":"ref217","doi-asserted-by":"crossref","unstructured":"Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, et al. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica. 2018; 136: 389\u2013404.","DOI":"10.1007\/s00401-018-1878-z"},{"key":"ref218","doi-asserted-by":"crossref","unstructured":"Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. Journal of Neuropathology and Experimental Neurology. 2008; 67: 555\u2013564.","DOI":"10.1097\/NEN.0b013e31817713b5"},{"key":"ref219","doi-asserted-by":"crossref","unstructured":"Robinson AC, Thompson JC, Weedon L, Rollinson S, Pickering-Brown S, Snowden JS, et al. No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease. Neuropathology and Applied Neurobiology. 2014; 40: 844\u2013854.","DOI":"10.1111\/nan.12155"},{"key":"ref220","doi-asserted-by":"crossref","unstructured":"Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. Journal of Neuropathology and Experimental Neurology. 2008; 67: 1159\u20131165.","DOI":"10.1097\/NEN.0b013e31818e8951"},{"key":"ref221","doi-asserted-by":"crossref","unstructured":"Maat-Schieman M, Roos R, Losekoot M, Dorsman J, Welling-Graafland C, Hegeman-Kleinn I, et al. Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington\u2019s disease. Brain Pathology (Zurich, Switzerland). 2007; 17: 31\u201337.","DOI":"10.1111\/j.1750-3639.2006.00040.x"},{"key":"ref222","doi-asserted-by":"crossref","unstructured":"Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. The Journal of Biological Chemistry. 2002; 277: 7466\u20137476.","DOI":"10.1074\/jbc.M103946200"},{"key":"ref223","doi-asserted-by":"crossref","unstructured":"Koga S, Lin WL, Walton RL, Ross OA, Dickson DW. TDP-43 pathology in multiple system atrophy: colocalization of TDP-43 and \u03b1-synuclein in glial cytoplasmic inclusions. Neuropathology and Applied Neurobiology. 2018; 44: 707\u2013721.","DOI":"10.1111\/nan.12485"},{"key":"ref224","doi-asserted-by":"crossref","unstructured":"Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica. 2007; 114: 221\u2013229.","DOI":"10.1007\/s00401-007-0261-2"},{"key":"ref225","doi-asserted-by":"crossref","unstructured":"McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer\u2019s disease, dementia with Lewy bodies and ageing. Brain Pathology (Zurich, Switzerland). 2017; 27: 472\u2013479.","DOI":"10.1111\/bpa.12424"},{"key":"ref226","doi-asserted-by":"crossref","unstructured":"Arai T, Mackenzie IRA, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, et al. Phosphorylated TDP-43 in Alzheimer\u2019s disease and dementia with Lewy bodies. Acta Neuropathologica. 2009; 117: 125\u2013136.","DOI":"10.1007\/s00401-008-0480-1"},{"key":"ref227","doi-asserted-by":"crossref","unstructured":"Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, et al. Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration. 2019; 14: 5.","DOI":"10.1186\/s13024-019-0306-8"},{"key":"ref228","doi-asserted-by":"crossref","unstructured":"Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer\u2019s disease and dementia with Lewy bodies. Brain Research. 2007; 1184: 284\u2013294.","DOI":"10.1016\/j.brainres.2007.09.048"},{"key":"ref229","doi-asserted-by":"crossref","unstructured":"Yokota O, Davidson Y, Arai T, Hasegawa M, Akiyama H, Ishizu H, et al. Effect of topographical distribution of \u03b1-synuclein pathology on TDP-43 accumulation in Lewy body disease. Acta Neuropathologica. 2010; 120: 789\u2013801.","DOI":"10.1007\/s00401-010-0731-9"},{"key":"ref230","doi-asserted-by":"crossref","unstructured":"Tian T, Huang C, Tong J, Yang M, Zhou H, Xia XG. TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. International Journal of Biological Sciences. 2011; 7: 234\u2013243.","DOI":"10.7150\/ijbs.7.234"},{"key":"ref231","doi-asserted-by":"crossref","unstructured":"Shen L, Wang C, Chen L, Leung KL, Lo E, Lakso M, et al. TDP-1\/TDP-43 potentiates human \u03b1-Synuclein (HASN) neurodegeneration in Caenorhabditis elegans. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2020; 1866: 165876.","DOI":"10.1016\/j.bbadis.2020.165876"},{"key":"ref232","doi-asserted-by":"crossref","unstructured":"Fujishiro H, Uchikado H, Arai T, Hasegawa M, Akiyama H, Yokota O, et al. Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathologica. 2009; 117: 151\u2013158.","DOI":"10.1007\/s00401-008-0463-2"},{"key":"ref233","doi-asserted-by":"crossref","unstructured":"Koga S, Murakami A, Martin NB, Dickson DW. The frequency and distribution of TDP-43 pathology in argyrophilic grain disease. Journal of Neuropathology and Experimental Neurology. 2023; 82: 739\u2013741.","DOI":"10.1093\/jnen\/nlad042"},{"key":"ref234","doi-asserted-by":"crossref","unstructured":"Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathologica. 2013; 126: 51\u201357.","DOI":"10.1007\/s00401-013-1110-0"},{"key":"ref235","doi-asserted-by":"crossref","unstructured":"Nascimento C, Suemoto CK, Rodriguez RD, Alho ATDL, Leite RP, Farfel JM, et al. Higher Prevalence of TDP-43 Proteinopathy in Cognitively Normal Asians: A Clinicopathological Study on a Multiethnic Sample. Brain Pathology (Zurich, Switzerland). 2016; 26: 177\u2013185.","DOI":"10.1111\/bpa.12296"},{"key":"ref236","doi-asserted-by":"crossref","unstructured":"Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathologica. 2017; 134: 187\u2013205.","DOI":"10.1007\/s00401-017-1709-7"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/28\/10\/10.31083\/j.fbl2810255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:51:14Z","timestamp":1732715474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/28\/10\/10.31083\/j.fbl2810255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":236,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2768-6701(23)01060-2"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2810255","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"article-number":"255"}}